Switch theme
Sign up to access all valuation multiples
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
2002
357
LTM Revenue $678M
LTM EBITDA $416M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Collegium Pharmaceutical has a last 12-month revenue (LTM) of $678M and a last 12-month EBITDA of $416M.
In the most recent fiscal year, Collegium Pharmaceutical achieved revenue of $631M and an EBITDA of $342M.
Collegium Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Collegium Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $678M | XXX | $631M | XXX | XXX | XXX |
| Gross Profit | $678M | XXX | $377M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $416M | XXX | $342M | XXX | XXX | XXX |
| EBITDA Margin | 61% | XXX | 54% | XXX | XXX | XXX |
| EBIT | $409M | XXX | $167M | XXX | XXX | XXX |
| EBIT Margin | 60% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $260M | XXX | $69.2M | XXX | XXX | XXX |
| Net Margin | 38% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $782M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Collegium Pharmaceutical's stock price is $29.
Collegium Pharmaceutical has current market cap of $936M, and EV of $1.6B.
See Collegium Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $936M | XXX | XXX | XXX | XXX | $6.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Collegium Pharmaceutical has market cap of $936M and EV of $1.6B.
Collegium Pharmaceutical's trades at 2.5x EV/Revenue multiple, and 4.6x EV/EBITDA.
Equity research analysts estimate Collegium Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Collegium Pharmaceutical has a P/E ratio of 3.6x.
See valuation multiples for Collegium Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $936M | XXX | $936M | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 3.8x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBIT | 3.9x | XXX | 9.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 3.6x | XXX | 13.5x | XXX | XXX | XXX |
| EV/FCF | 6.4x | XXX | 7.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCollegium Pharmaceutical's last 12 month revenue growth is 11%
Collegium Pharmaceutical's revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $0.6M for the same period.
Collegium Pharmaceutical's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Collegium Pharmaceutical's rule of X is 90% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Collegium Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 61% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 65% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 90% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Collegium Pharmaceutical acquired XXX companies to date.
Last acquisition by Collegium Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Collegium Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Collegium Pharmaceutical founded? | Collegium Pharmaceutical was founded in 2002. |
| Where is Collegium Pharmaceutical headquartered? | Collegium Pharmaceutical is headquartered in United States of America. |
| How many employees does Collegium Pharmaceutical have? | As of today, Collegium Pharmaceutical has 357 employees. |
| Who is the CEO of Collegium Pharmaceutical? | Collegium Pharmaceutical's CEO is Mr. Vikram Karnani. |
| Is Collegium Pharmaceutical publicy listed? | Yes, Collegium Pharmaceutical is a public company listed on NAS. |
| What is the stock symbol of Collegium Pharmaceutical? | Collegium Pharmaceutical trades under COLL ticker. |
| When did Collegium Pharmaceutical go public? | Collegium Pharmaceutical went public in 2015. |
| Who are competitors of Collegium Pharmaceutical? | Similar companies to Collegium Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Collegium Pharmaceutical? | Collegium Pharmaceutical's current market cap is $936M |
| What is the current revenue of Collegium Pharmaceutical? | Collegium Pharmaceutical's last 12 months revenue is $678M. |
| What is the current revenue growth of Collegium Pharmaceutical? | Collegium Pharmaceutical revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Collegium Pharmaceutical? | Current revenue multiple of Collegium Pharmaceutical is 2.3x. |
| Is Collegium Pharmaceutical profitable? | Yes, Collegium Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Collegium Pharmaceutical? | Collegium Pharmaceutical's last 12 months EBITDA is $416M. |
| What is Collegium Pharmaceutical's EBITDA margin? | Collegium Pharmaceutical's last 12 months EBITDA margin is 61%. |
| What is the current EV/EBITDA multiple of Collegium Pharmaceutical? | Current EBITDA multiple of Collegium Pharmaceutical is 3.8x. |
| What is the current FCF of Collegium Pharmaceutical? | Collegium Pharmaceutical's last 12 months FCF is $246M. |
| What is Collegium Pharmaceutical's FCF margin? | Collegium Pharmaceutical's last 12 months FCF margin is 36%. |
| What is the current EV/FCF multiple of Collegium Pharmaceutical? | Current FCF multiple of Collegium Pharmaceutical is 6.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
